CTNI-52. SURVIVAL OUTCOMES IN RECURRENT GLIOBLASTOMA (RGBM) PATIENTS TREATED WITH A SINGLE INTRA-TUMORAL ADMINISTRATION OF BIZAXOFUSP, AN IL-4R-TARGETING TOXIN, IN A PHASE IIB TRIAL

Overview of attention for article published in Neuro-Oncology, November 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#14 of 3,462)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

So far, Altmetric has seen 44 news stories from 43 outlets.

Medicenna Therapeutics Corp. recently announced a poster presentation and an oral summary highlighting longer term follow up…

GlobeNewswire 2023-11-17 TORONTO and HOUSTON, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp.

Single treatment of bizaxofusp doubled mOS (14.5 months vs. 7.2 months) irrespective of IL4R expression (high or low) compared…

Single treatment of bizaxofusp doubled mOS (14.5 months vs. 7.2 months) irrespective of IL4R expression (high or low) compared…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 40 additional news stories.